clinical trial · NCT07105098
NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
SchizophreniaNBI-1117568Placebo
brief summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
started
Aug 11, 2025
primary completion
Nov 1, 2027
completion
Nov 1, 2027
last updated
Apr 15, 2026
official title
A Global, Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1117568 in Adults With Schizophrenia Who Warrant Inpatient Hospitalization
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol